The intravitreal injection of anti-VEGF agents has become the first choice for the treatment of neovascular AMD, and is believed to be the most general and effective protection against exacerbation not only in AMD [13,14,15], but also in other sight-threatening diseases accompanied by neovascularization [16,17]. The gene discussed is VEGFA; the disease is age-related macular degeneration.